Heartbeam, a US-based cardiac technology company, has significantly developed artificial intelligence (AI) applied to vector electrocardiography (VECG) technology.
HeartBeam’s core VECG technology captures signals in three dimensions (X, Y, Z) to capture a 3D map of the heart’s electrical activity and converts it into an interpretable 12-lead ECG. The company’s flagship device is HeartBeam AIMIGo, a credit card-sized platform that stays close to the patient and generates comprehensive data for AI applications.
The device aims to mimic a physician’s decision-making process and automate the evaluation of patients with cardiac symptoms. By integrating AI into the analysis process, we aim to improve diagnostic accuracy.
The company’s strategic moves include the appointment of new leadership and advisory roles, including Mohamed Shokuhi Yekuta, senior director of machine learning, and Lance Myers, who has been named chief AI advisor. Shokoohi most recently worked at Microsoft to improve the accuracy of software tools, while Myers previously served as head of cardiovascular devices at Verily Life Sciences.
In an announcement accompanying the latest development, HeartBeam CEO Branislav Vajdic said: “By pioneering a user-friendly device that enables long-term, frequent 12-lead ECGs, and combining AI with our proprietary VECG technology that can go beyond 12-lead ECGs, HeartBeam will ultimately improve patient care. We are in a good position to identify subtle cardiac trends that can be improved.”
HeartBeam was founded in 2015 and is headquartered in California, USA. The company was granted its third US patent for the AIMIGo device last month, and the US Patent and Trademark Office has granted the company 11 patents in the US, for a total of 15 patents.
Access the most comprehensive company profiles on the market with GlobalData. Save research time. Increase competitiveness.
Company Profile – Free Sample
You will receive a download email shortly
We are confident in the unique quality of our company profile. However, we want you to make the decision that is most beneficial for your business, so we are offering free samples that you can download by submitting the form below.
by global data
In October, UK-based Anumana partnered with Mayo Clinic to receive FDA approval for ECG-AI LEF, an AI-powered medical device designed to detect low ejection fraction (LEF) in patients at risk of heart failure. Obtained 510(k) authorization.
According to GlobalData analysis, the approval of Anumana’s ECG-AI LEF represents a major advance in healthcare by addressing the critical need for early detection of heart-related problems.
